Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pirtobrutinib is a BTK inhibitor developed by Eli Lilly and Company in the United States. It was first approved by the U.S. Food and Drug Administration (FDA) on January 27, 2023.I···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：259
During treatment with pirtobrutinib, some side effects may occur, and these effects vary from person to person. Before receiving pirtobrutinib treatment, patients need to thoroughl···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：254
For Patients with Severe Renal Impairment(1). If the current dose is 200 mg once daily, reduce the pirtobrutinib dose to 100 mg once daily.(2). If the current dose is other than 20···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：299
Pirtobrutinib is a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor developed by Eli Lilly in the United States. It was first approved by the U.S. FDA on Janu···【more】
Article source：Captain MedicineRelease date：2026-03-25Recommended：287
Enasidenib helps restore the normal differentiation of leukemia cells by inhibiting the activity of mutant IDH2 enzymes. During treatment, it may also affect the function of normal···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：199
The dosage and administration of enasidenib must strictly follow medical advice and be conducted under the guidance of a qualified physician. Do not adjust the dose or stop taking ···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：191
The use of tepotinib must strictly adhere to the principle of individualized treatment. The administration and dosage should be determined by a qualified physician based on the pat···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：225
Side Effects of TepotinibPatients should schedule regular follow-ups during treatment with Tepotinib and closely monitor any changes in their physical condition. If symptoms such a···【more】
Article source：Captain MedicineRelease date：2026-03-24Recommended：225
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Sotorasib (Lumakras) for the treatment of adult patients with KRAS G12C-mutated local···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：222
On January 17, 2025, Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Sotorasib (Lumakras) and Panitumumab (Vectibix) for the treatm···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：238
KRAS mutations have long been considered a major challenge in cancer research, remaining difficult to target for many years. The launch of Sotorasib has changed this landscape, off···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：206
Sotorasib is a KRASG12C inhibitor developed by Amgen. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2021 and was subsequently launched.I.···【more】
Article source：Captain MedicineRelease date：2026-03-23Recommended：200
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
